Avacopan

An growing therapeutic armamentarium for antineutrophil cytoplasmic antibody-associated vasculitis — including avacopan and azathioprine — is providing rheumatologists with an increasingly robust array of options, according to a presenter.

DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for patients with ANCA-associated vasculitis, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.

SAN DIEGO — In patients with ANCA-associated vasculitis, avacopan and rituximab may offer an alternative to glucocorticoids-based management, according to a presenter at the Congress of Clinical Rheumatology West.

During Vasculitis Awareness Month in May, patient advocacy organizations face the challenge of raising awareness for a rare disease with many different manifestations and states.

In a randomized, double-blind, controlled study, Tavneos showed a significantly greater increase in glomerular filtration rate compared with prednisone in patients with renal disease associated with anti-neutrophil cytoplasmic antibody vasculitis.

Avacopan yielded significantly better kidney function outcomes than prednisone in a cohort of patients with renal disease associated with anti-neutrophil cytoplasmic antibody vasculitis, according to data presented at ACR Convergence 2021.

Despite an ever-growing array of potential candidate biomarkers for antineutrophil cytoplasmic antibody-associated vasculitis, it can be a long journey from “bench work” to bedside, according to a presenter at ACR Convergence 2021.

Patients with ANCA-associated vasculitis who received avacopan showed greater recovery of kidney function compared with patients who received prednisone, according to study results presented at ASN Kidney Week.

The FDA has approved avacopan as an adjunctive treatment for adults with severe active ANCA-associated vasculitis, specifically granulomatosis with polyangiitis and microscopic polyangiitis, alongside standard therapy.